Latest Asx Listing News

Kingsgate Consolidated updates its 2025 Mineral Resources and Ore Reserves, introducing a maiden estimate for the Chatree South-East Complex while reporting modest declines in overall Ore Reserves.

Findi Limited has responded to ASX inquiries about unusual stock price and volume movements, denying any undisclosed information and announcing legal action against a former subsidiary executive for misleading social media posts.

Beam Dental Bidco Pty Ltd has launched an unconditional $2.20 per share takeover bid for Pacific Smiles Group Limited, offering a 37.5% premium and aiming to consolidate full ownership. The offer is unanimously recommended by Pacific Smiles’ Independent Board Committee, with plans to delist the company from the ASX upon success.

Carawine Resources Limited’s shares have been suspended from trading following a Federal Court ruling that allows QGold Pty Ltd to compulsorily acquire all remaining shares it does not own.

Nordic Resources Ltd attributes its recent share price and volume spike to a successful investor roadshow and capital raising tied to its new Finland gold projects, while confirming full ASX compliance.

Discovery Alaska Limited has detailed its exploration expenditures and strategic pivot from Alaskan projects to new US acquisitions, affirming its financial health and operational sufficiency to maintain its ASX listing.

Wellard Limited has received a final Australian Taxation Office ruling confirming its recent 15 cents-per-share return of capital is not taxable as a dividend, clarifying the tax implications for shareholders following the sale of its last revenue-generating asset.

Wellard Limited has formally requested to delist from the ASX following the sale of its final revenue-generating vessel, aiming to reduce costs and return excess cash to shareholders. The move awaits shareholder approval at the upcoming AGM.

Uvre Limited has gained approval for a secondary listing on the New Zealand Stock Exchange, complementing its ASX listing and enhancing access to New Zealand investors. This move aligns with its expanding gold exploration projects across New Zealand.

PYC Therapeutics has reported positive safety outcomes from its Phase 1 trial of PYC-001 for Autosomal Dominant Optic Atrophy, paving the way for a global Phase 1/2 study later this year.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

Austral Resources Australia Limited has extended the closing date for its $40 million placement offer to 20 October 2025, alongside an ASX suspension extension to 31 October to meet reinstatement conditions.